Does Medicare Cover GLP-1 Drugs? (2026)

Direct answer: does Medicare cover GLP-1 drugs?

It depends on why your doctor prescribed the drug. Medicare Part D and Medicare Advantage prescription drug plans cover GLP-1 medications such as Ozempic, Mounjaro, and Rybelsus when prescribed for type 2 diabetes in 2026, subject to each plan's formulary and prior authorization rules. Medicare still excludes GLP-1 drugs prescribed only for weight loss, except Wegovy for beneficiaries with cardiovascular disease and the 2026-2027 GLP-1 Bridge Program's $50 monthly copay for chronic weight management.

What Original Medicare Part D covers for GLP-1 drugs

Original Medicare does not include outpatient prescription drug coverage inside Medicare Part A or Medicare Part B, so GLP-1 medications dispensed at a retail or mail-order pharmacy are covered through a standalone Medicare Part D Prescription Drug Plan (PDP) or the drug portion of a Medicare Advantage plan (MA-PD). For type 2 diabetes, Part D plans in 2026 generally cover semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) because the FDA approved these specific drugs for glycemic control, and federal Part D rules require plans to cover a range of drugs within key therapeutic categories, including GLP-1 receptor agonists.

Coverage still depends on your specific plan. Every Part D and MA-PD plan publishes an annual formulary listing covered drugs by tier, and GLP-1 drugs for diabetes typically sit in a higher cost-sharing tier with coinsurance of roughly 25% to 33% until you reach the 2026 Part D out-of-pocket cap of $2,100. Many plans also require step therapy, such as trying metformin first, or prior authorization confirming a type 2 diabetes diagnosis before approving Ozempic, Mounjaro, or Rybelsus. Beneficiaries can compare formularies for their exact drug and dose using the Medicare Plan Finder at medicare.gov before each Annual Election Period.

What Medicare Advantage may add in 2026

Medicare Advantage prescription drug plans (MA-PD) must follow the same federal formulary rules as standalone Part D plans, so an MA-PD cannot cover GLP-1 drugs for weight loss any more broadly than Original Medicare allows. What MA-PD plans can add are supplemental benefits that support weight management indirectly, such as nutrition counseling, gym memberships through programs like SilverSneakers, and, in some plans, coverage of bariatric surgery consultations. A growing number of 2026 Medicare Advantage plans also participate in the GLP-1 Bridge Program alongside standalone PDPs, so beneficiaries in an MA-PD plan and beneficiaries in Original Medicare with a standalone PDP have equal access to the $50 monthly copay for Wegovy, Zepbound, and Foundayo through the Bridge.

The weight-loss exclusion and its 2026 exceptions

Federal law has excluded weight-loss drugs from Medicare Part D since the program began. The Medicare Modernization Act of 2003 wrote this exclusion into Social Security Act Section 1927(d)(2)(A), classifying anti-obesity medications alongside cosmetic drugs and fertility drugs as categories Part D plans are barred from covering, regardless of what an individual plan might want to do. That statutory language is why Wegovy, Zepbound, and any GLP-1 drug labeled purely for chronic weight management sat outside Part D for two decades.

Two exceptions opened the door starting in 2024 and 2026. First, the FDA approved Wegovy in March 2024 to reduce major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and overweight or obesity, and CMS confirmed Part D plans may cover Wegovy for that specific cardiovascular indication because it is no longer solely a weight-loss drug. Second, the Medicare GLP-1 Bridge Program runs from July 1, 2026 through December 31, 2027 as a CMS demonstration, letting eligible beneficiaries access Wegovy, Zepbound (KwikPen), or Foundayo for chronic weight management at a flat $50 monthly copayment, separate from the regular Part D deductible and the 2026 out-of-pocket cap.

Cost without Medicare coverage in 2026

Outside the cardiovascular indication and the Bridge Program, a Medicare beneficiary paying cash for a GLP-1 drug prescribed only for weight loss faces list prices of roughly $1,000 to $1,500 a month for Wegovy, Zepbound, or Ozempic in 2026, depending on the pharmacy and dose. Manufacturer savings cards that lower these prices for commercially insured patients generally cannot be used by Medicare beneficiaries because federal anti-kickback rules bar drug manufacturers from offering retail coupons to people enrolled in a federal healthcare program.

That leaves patient assistance foundations, the manufacturer's own income-based charity programs, and, for some beneficiaries, cheaper diabetes-indicated GLP-1 alternatives as the main lower-cost paths outside the Bridge Program. Beneficiaries should also avoid unregulated compounded semaglutide or tirzepatide sold by cash-pay telehealth clinics, since the FDA has issued repeated safety warnings about inconsistent dosing and unverified active ingredients in compounded versions.

Finding a Part D plan that covers your GLP-1 drug

Formulary coverage for GLP-1 drugs changes every plan year, so the most reliable way to confirm 2026 coverage is to search the Medicare Plan Finder at medicare.gov with your exact drug name, dose, and pharmacy. The tool shows which tier your drug falls into, whether prior authorization or step therapy applies, and your estimated cost at each stage of the Part D benefit, including the 2026 out-of-pocket cap of $2,100. Because plans can add or drop GLP-1 drugs from their formulary each January, beneficiaries who rely on Ozempic, Mounjaro, or Rybelsus for diabetes should re-check their plan's formulary every fall during the Medicare Annual Election Period, which runs October 15 through December 7, 2026 for coverage starting January 1, 2027.

Alternatives if Medicare does not cover your GLP-1 prescription

Beneficiaries who do not qualify for the Wegovy cardiovascular indication or the GLP-1 Bridge Program have several fallback options in 2026. Patient assistance programs run directly by manufacturers such as Novo Nordisk and Eli Lilly offer free or reduced-cost medication to low-income applicants who meet income limits, and these programs generally do accept Medicare beneficiaries because they operate outside the federal anti-kickback restriction on retail coupons.

• Apply for the Medicare GLP-1 Bridge Program through your Part D or MA-PD plan once it opens July 1, 2026, if your provider confirms a qualifying BMI and condition such as hypertension, pre-diabetes, or chronic kidney disease.
• Ask your prescriber about a diabetes-indicated GLP-1 (Ozempic, Mounjaro, Rybelsus) if you have type 2 diabetes alongside excess weight, since the diabetes indication is far more likely to be covered.
• Check whether your State Pharmaceutical Assistance Program (SPAP) supplements Part D drug costs; several states help cover high-tier drugs like GLP-1 medications.
• If you have both Medicare and Medicaid (dual-eligible), check Medicaid coverage of GLP-1 drugs for weight loss in your state, since rules differ significantly by state Medicaid program.
• If you leave Medicare for an ACA-compliant marketplace plan before turning 65, some state-mandated essential health benefits require anti-obesity medication coverage that Medicare does not provide; insurers cannot deny you for a preexisting condition like obesity or type 2 diabetes, though drug formularies still vary by plan.

Does a Medicare Part D plan cover Ozempic for type 2 diabetes?

Yes, in most cases. A standalone Medicare Part D plan or the drug portion of a Medicare Advantage plan covers Ozempic for type 2 diabetes in 2026 when the drug is on your plan's formulary. Most Part D plans place Ozempic in a higher-cost tier with coinsurance around 25% to 33% until you reach the 2026 Part D out-of-pocket cap of $2,100. Check the Medicare Plan Finder at medicare.gov to confirm your plan covers it.

Does Medicare Advantage cover GLP-1 drugs differently than Original Medicare?

No. Medicare Advantage prescription drug plans (MA-PD) must follow the same federal Part D rules as standalone plans, so they cannot cover GLP-1 weight-loss drugs more broadly than the law allows. MA-PD plans can add supplemental benefits like nutrition counseling or gym access that support weight management, and many participate in the 2026-2027 GLP-1 Bridge Program on equal terms with standalone Part D plans.

What is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a CMS demonstration running July 1, 2026 through December 31, 2027 that lets eligible Part D and MA-PD beneficiaries access Wegovy, Zepbound (KwikPen), or Foundayo for chronic weight management at a flat $50 monthly copay. Eligibility requires a provider to confirm a qualifying BMI plus a condition such as cardiovascular disease, hypertension, pre-diabetes, or chronic kidney disease. The $50 copay does not count toward the regular Part D out-of-pocket cap.

Does Medicare cover Wegovy?

It depends on the diagnosis. Medicare covers Wegovy in 2026 when prescribed to reduce cardiovascular events in beneficiaries with established heart disease and overweight or obesity, an indication the FDA approved in March 2024. Medicare also covers Wegovy through the GLP-1 Bridge Program (July 2026 through December 2027) at a $50 monthly copay for qualifying beneficiaries. Wegovy prescribed solely for weight loss outside those two paths is not covered.

How much do GLP-1 drugs cost without Medicare coverage in 2026?

GLP-1 drugs prescribed only for weight loss typically cost $1,000 to $1,500 a month out of pocket in 2026 when Medicare does not cover them, depending on the drug, dose, and pharmacy. Diabetes-indicated GLP-1 drugs like Ozempic or Mounjaro, when covered by a Part D formulary, usually cost far less: a coinsurance percentage of the drug's negotiated price until you hit the 2026 Part D out-of-pocket cap of $2,100.

Can I use a manufacturer savings card with Medicare?

Generally no. Federal anti-kickback rules bar pharmaceutical manufacturers from offering copay coupons or savings cards to people enrolled in a federal healthcare program like Medicare, even though those same cards are widely used by commercially insured patients. Medicare beneficiaries who need help affording a GLP-1 drug should instead look at manufacturer patient assistance foundations, which use income-based eligibility rather than a retail coupon.

What are alternatives if my Medicare plan does not cover my GLP-1 drug?

Options include applying for the 2026-2027 GLP-1 Bridge Program if you qualify, asking your prescriber about a diabetes-indicated GLP-1 if you have type 2 diabetes, checking a manufacturer patient assistance program, checking whether your state's Pharmaceutical Assistance Program supplements Part D costs, and, for dual-eligible beneficiaries, checking your state Medicaid program's GLP-1 weight-loss drug rules, which vary significantly by state.

Is there a difference between GLP-1 coverage for diabetes versus weight loss under Medicare?

Yes, a significant one. Medicare Part D and MA-PD plans generally cover GLP-1 drugs like Ozempic, Mounjaro, and Rybelsus when prescribed for type 2 diabetes, subject to formulary and prior authorization rules. The same class of drugs, or their weight-loss branded versions like Wegovy and Zepbound, are excluded by federal law when prescribed solely for weight loss, except for the Wegovy cardiovascular indication and the 2026-2027 GLP-1 Bridge Program.